Yahoo Finance

Sumitomo Pharma America Announces that its Investigational Therapy DSP-3077 Has Received FDA Orphan Drug Designation for the Treatment of Retinitis Pigmentosa

– DSP-3077, an investigational allogeneic iPS cell-derived retinal sheet (3-dimensional [3D] retina), is being evaluated in patients in a Phase 1/2 study – – Retinitis pigmentosa (RP) is a group of ...
Yahoo Finance

Ray Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RTx-015 in Retinitis Pigmentosa

BERKELEY, Calif., April 01, 2026--(BUSINESS WIRE)--Ray Therapeutics (RayTx), a clinical-stage biopharmaceutical company pioneering optogenetic therapies for those living with retinal degenerative ...
Morningstar%2c Inc.

Nanoscope Therapeutics Announces U.S. Food and Drug Administration Acceptance of Biologics License Application for MOGENRY for the Treatment of Retinitis Pigmentosa with Severe ...

DALLAS, Sept. 9, 2026 /PRNewswire/ -- Nanoscope Therapeutics, Inc. ("Nanoscope"), a biotechnology company focused on developing and commercializing novel, disease‑agnostic therapies for patients with ...
Medical Xpress

Fears of potentially blinding complication from Avastin eye injections overblown, study says

Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endophthalmitis, a potentially blinding eye infection, than injections with the much more expensive drug ...
Reuters

US FDA approves Outlook Therapeutics' eye disease drug

July 24 (Reuters) - Outlook Therapeutics (OTLK.O), opens new tab said on Friday the U.S. Food and Drug Administration has approved its drug for a type of ‌eye disease that can cause vision loss. The ...